Answers are grounded in this paper and cite their sources.
Histone lysine lactylation (Kla), induced by lactate in tumor microenvironment, might be a novel therapeutic target for cancer. Lung adenocarcinoma (LUAD) was characterized by lactate accumulation in the TME. However, the role of histone Kla in lung LUAD is unclear. The RNA expression profile of LUAD was downloaded from The Cancer Genome Atlas (TCGA), and then selected differentially expressed Kla-specific genes (DEKlaGs), following building a prognostic model to predict the prognosis of patients with LUAD. On the other hand, we investigated the roles of prognostic biomarkers in the LUAD immune microenvironment, and determined its roles in the LUAD therapy response. Finally, the potential KEGG pathways influenced by histone Kla were investigated through gene set enrichment analysis (GSEA). A total of eighty-six DEKlaGs were identified with the cut-off criteria log2FC ≥ 2 and p-value<0.05. Four prognostic DEKlaGs, including C1QTNF6, HCN2, SLAMF9, and IL20RB, were enrolled in the Cox regression model. We showed that high expression of lactate production-associated genes was correlated with the expression of prognostic biomarkers. On the other hand, the activation of Kla was related to LUAD immune infiltration, and played a crucial role in LUAD drug resistance and immunotherapy resistance. Moreover, Kla was associated with the activation of MARK, NOTCH, JAK/STAT signaling pathways, and contributed to the focal adhesion of LUAD. In conclusion, C1QTNF6, HCN2, SLAMF9, and IL20RB induced by histone Kla might be crucial effective biomarkers for LUAD, suggesting that Kla was expected to be a novel therapeutic target for LUAD.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: